You are here

AAT-MSCs Improves Innate Properties of MSCs

Mesenchymal stem cell (MSC) therapy represents an exciting new means to treat autoimmune and inflammatory diseases; however, most human studies using MSCs alone have failed to achieve the sustained suppression of the autoimmune response. Researchers led by Charlie Strange and Hongjun Wang (Medical University of South Carolina, Charleston, South Carolina, USA) have now generated alpha‐1 antitrypsin (AAT)‐overexpressing MSCs that displayed improved intrinsic properties and sustained efficacy in the prevention of type 1 diabetes onset, an autoimmune disease. For all the details of this exciting new study, see STEM CELLS Translational Medicine.